Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05312879 · ClinicalTrials.gov registry record · Phase 2
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
A Phase 2 study of Proteinuric Kidney Disease, sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 466
- Enrollment target
- 20
- Study locations
NCT05312879 is a Phase 2 study of Proteinuric Kidney Disease that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 466 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT05312879, a Phase 2 study of Proteinuric Kidney Disease, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 466 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VX-147
Study Locations (20)
Alabama
- Alabama Kidney Research - Alabaster
- EmVenio Research - Mobile Unit - Birmingham - Birmingham
- Cardiology, P.C. - Birmingham
- Children's Hospital of Alabama - Birmingham
- The Kirklin Clinic - Nephrology - Birmingham
- Nephrology Associates - Fairhope
- Heart Center Research LLC - Huntsville
- Nephrology Consultants, LLC - Huntsville
- Renal Associates of Alabama, LLC - Montgomery
California
- The Medical Research Group - Saint Agnes Medical Center - Fresno
- Amicis Research Center - Balboa - Granada Hills
- Kidney Care Center of North Valley - Granada Hills
- Eastside Clinical Research Associates - Los Angeles
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
Arizona
- Arizona Kidney Disease and Hypertension Center - Banner Desert Office - Mesa
- Arizona Kidney Disease and Hypertension Center - Thomas Office - Phoenix
- Phoenix Children's Hospital, Inc. - Nephrology - Phoenix
Arkansas
- CHI St. Vincent Heart Clinic Arkansas- Cardiology and Medicine Clinic - Little Rock - Little Rock
- UAMS Medical Center - Pulmonology - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 466 participants |
| Start Date | 2022-03-30 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05312879
The ClinicalTrials.gov registry entry for NCT05312879 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 466 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Proteinuric Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05312879 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Alabama, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05312879 about?
NCT05312879 is a clinical study titled "Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease". The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
What is the current status of trial NCT05312879?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 466 participants. The study started on 2022-03-30. Estimated completion is 2026-06-30.
What conditions does trial NCT05312879 study?
This clinical trial studies the following conditions: Proteinuric Kidney Disease.
What interventions are being tested in trial NCT05312879?
The interventions under investigation include: Placebo (DRUG), VX-147 (DRUG).
Who is sponsoring clinical trial NCT05312879?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05312879 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Proteinuric Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.